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Introduction {#sec001}
============

Acute myeloid leukemia (AML) is a type of heterogeneous clonal diseases characterized by hematopoietic progenitor cells or blasts cell that fail to normal regulation of differentiation, proliferation and apoptosis, and instead remain blocked at aggressive expansion stage of development \[[@pone.0236124.ref001], [@pone.0236124.ref002]\]. Even the genomic and ergonomic pathogenesis is becoming clear and new chemotherapeutic strategies have been well applied in clinical practices over the past 20 years, the prognosis of AML is still dismal \[[@pone.0236124.ref003]\]. Although the treatment-related mortality of AML, like infections and hemorrhage has significantly decreased with the improved supportive care, multidrug resistance remains the major cause of relapse and poor prognosis \[[@pone.0236124.ref004]\]. For this reason, it is crucial to discover and identify predictive molecular markers with prognosis significance so that patients get better treatment in clinical practice.

Cross-talk between different tissue/cells and interaction with ECM can significantly affect the pathophysiological behavior of the disease, such as tumor resistance, migration and infiltration \[[@pone.0236124.ref005], [@pone.0236124.ref006]\]. These processes are mainly mediated by cell surface receptors. Accordingly, abnormal or overexpression of cytokine receptors may be closely related to the pathological status of patients with acute leukemia. CD25/IL2RA, the gene for interlekin-2 receptor subunit alpha that binds IL-2, is strongly expressed on regulatory T cell and activated T cells, which plays an vital role in regulation of T cell function and maintenance of immune tolerance through STAT dependent mechanisms \[[@pone.0236124.ref007], [@pone.0236124.ref008]\]. Upon binding its ligand IL-2, the IL-2 receptor induces T-cell proliferation and differentiation \[[@pone.0236124.ref009]\].

Until now, many studies have reported that increased CD25 expression was correlated with poor prognosis of AML patients \[[@pone.0236124.ref010]--[@pone.0236124.ref014]\], but still some other studies draw the conflicting conclusions \[[@pone.0236124.ref015]\]. this may have been caused by the limited samples size in addition to other factors. Thus, we performed this meta-analysis of relevant studies published on this topic, aiming to quantitatively clarify the prognostic value of CD25 expression level in AML and its potential value as a biomarker.

Materials and methods {#sec002}
=====================

Publication search {#sec003}
------------------

Literature search was carried out in PubMed, Embase and Web of science from inception to July 2019. The detailed search strategies for each database are reported in [S1 Table](#pone.0236124.s002){ref-type="supplementary-material"}. Reference lists in the identified studies were also manually reviewed to avoiding missing any potential data.

Selection criteria {#sec004}
------------------

Two authors screened the initially identified studies independently by screening the title and abstract. The full-text articles of potentially eligible studies were independently assessed by the same two authors according against the inclusion criteria, and any disagreement was resolved by consensus.

The inclusion criteria included a) classify CD25 expression as "high" and "low" or "positive" and "negative"; b) studies that investigated the association between change in CD25 expression level and clinical prognosis of AML patients, such as overall survival (OS), disease free survival (DFS), relapse free survival (RFS) and event free survival (EFS); c) studies with sufficient data to estimate hazard ratios (HRs) with 95% confidence intervals (CIs); d) the expression level of CD25 was definitively tested by standard molecular assays;

The cardinal reasons for exclusion were: a) duplicate studies, reviews and case reports; b) animal experiments or studies performed not based on patients; c) articles without the HRs and 95% CI or could not be calculated from available data.

Data extraction and quality assessment {#sec005}
--------------------------------------

For each included study, the following primary characters was independently collected according to the inclusion and exclusion criteria listed above in accordance with a predefined information sheet: the first author's name, year of publication, country of origin, ethnicity, sample size, positive threshold, sex distribution, the French-American-British (FAB), cytogenetic features, hazard ratio (HR) and 95% confidence interval (95%CI) related to CD25 expression, If HRs or their corresponding 95% CIs were not directly given, they were extracted using Kaplan-Meier survival curves by a method previously introduced by Tierney et al. \[[@pone.0236124.ref016]\]. Any disagreements were resolved by consensus.

The methodological quality of the included data was assessed using the Newcastle-Ottawa-Scale (NOS). the NOS consisted of three aspects: selection, comparability and exposure. The highest rating is 9 scores, which assigned 4, 2 and 3 points for the three aspects, respectively. The study scoring 6 points or more was considered as high-quality.

Statistical analysis {#sec006}
--------------------

The HRs and the corresponding 95% CIs were used to evaluate the association for OS and DFS/EFS/RFS in AML. Due to the similar definitions of DFS, EFS and RFS and the limited number of studies enrolled, we combined the three clinical endpoints together in our analysis. If both univariate and multivariate analyses results were reported in the study, the latter results were used. A fixed or random-effect model was applied according to the heterogeneity across the studies, heterogeneity assumption was checked using I-squared test, and I^2^ \> 50% indicated the presence of heterogeneity, then the random effect model was applied for the pooled HRs, otherwise, the fixed effect model was applied. Subgroup analysis was carried out based on the ethnicity of each study (Caucasian/Asian), statistical method (Univariate/Multivariate), detection Method (Flow Cytometry/non-Flow Cytometry), the Cut-off value (10%/others) and included AML subtype (AML as a whole/AML without M3) that was represented in at least three separate studies. Funnel plots was utilized to indicate publication bias \[[@pone.0236124.ref017]\]. All the statistical analyses were carried out with software R language 3.6.0 (R Foundation for Statistical Computing, Vienna, Austria). All P‑values were two‑sided, and P \< 0.05 was considered to indicate statistically significant differences.

Results {#sec007}
=======

Study selection and characteristics {#sec008}
-----------------------------------

The selection process for the records research is shown in the flow diagram ([Fig 1](#pone.0236124.g001){ref-type="fig"}). Briefly, a total of 169 articles were acquired from databases searching and other source. Eight of these articles were eliminated for irrelevant to AML and CD25 through reading the titles and abstracts. As a result, 31 full-text articles were reviewed. Eleven studies did not assess the prognosis of CD25, three studies perform analysis of co-expression molecules, four studies did not provide sufficient data to calculate outcomes, two of them were comments and three were not published in English. Ultimately, a total of 10 cohort studies fulfilled the preset criteria, including ten studies investigating the outcome of OS \[[@pone.0236124.ref010]--[@pone.0236124.ref015], [@pone.0236124.ref018]--[@pone.0236124.ref021]\] and six on DFS/RFS/EFS \[[@pone.0236124.ref010], [@pone.0236124.ref012], [@pone.0236124.ref013], [@pone.0236124.ref018], [@pone.0236124.ref019], [@pone.0236124.ref021]\].

![Flow diagram of the study review and inclusion process.](pone.0236124.g001){#pone.0236124.g001}

These cohort studies were published between 2009 and 2019 and included 1480 patients with AML. The detail characteristics about the included studies are summarized in [Table 1](#pone.0236124.t001){ref-type="table"}. Among these studies, six were conducted in Europe, and four in Asia. Eight studies were conducted retrospectively, and the remaining 2 were prospective investigations using hospital-based data. The hazard ration (HR) estimates and the corresponding confidence intervals (CIs) in 7 studies were directly extracted through multivariate analyses and those of 3 other cohorts were calculated from Kaplan-Meier survival curves. All of the patients were older than 15 years of age, two studies were conducted with elder patients aging 60 or more years. The study designs included patients with non-M3 AML in four studies and unselected FAB AML in six studies. Two detecting methods, including Flow cytometry (FC) and Real-time PCR, were used to assess the CD25 expression in these studies and FC was the most commonly used method. Different CD25 cut-off value was used to determine the expression level in each study. The quality score of each study as assessed by NOS ranked from 5--8, with a median value of 7, which indicated the methodological quality of the included studies was acceptable.

10.1371/journal.pone.0236124.t001

###### A. Characteristics of studies included in the meta-analysis on CD25-related combination markers.

B. The main features of the included studies for the prognostic meta-analysis.

![](pone.0236124.t001){#pone.0236124.t001g}

  Author         Year           Country       Ethnicity        Size        Age        Female     No. of High CD25   Sample type                                                                                                  Quality
  -------------- -------------- ------------- ---------------- ----------- ---------- ---------- ------------------ ------------------------------------------------------------------------------------------------------------ ------------------
  Terwijn        2009           Netherlands   Caucasian        65          18--60     31         41                 BM or PB                                                                                                     7
  Gonen          2012           USA           Caucasian        396         18--60     207        75                 BM or PB                                                                                                     6
  Cerny          2013           USA           Caucasian        45          29--83     24         14                 BM                                                                                                           5
  Miltiades      2014           Greece        Caucasian        61          NR         NR         NR                 BM or PB                                                                                                     5
  Nakase         2015           Japan         Asian            270         15--60     NR         54                 BM or PB                                                                                                     7
  Ikegawa        2016           Japan         Asian            66          NR         36         22                 BM                                                                                                           8
  Bołkun         2016           Poland        Caucasian        46          45--78     30         12                 PB                                                                                                           6
  Fujiwara       2017           Japan         Asian            154         ≥60        85         21                 BM                                                                                                           7
  Allan          2018           USA           Caucasian        58          ≥60        33         19                 BM                                                                                                           7
  Du             2019           China         Asian            239         15--65     127        48                 BM                                                                                                           7
  First Author   Study design   Cut-off       Subtype          Detection   HR value   Outcomes   Uni/Multivariate   Adjusted factors                                                                                             HR (95% CI)
  Terwijn        RC             10%           Non-M3           FC          KM         OS         Univariate         \-                                                                                                           2.00(1.35--2.94)
                                                                           KM         RFS        Univariate                                                                                                                      2.97(1.39--6.25)
  Gonen          RC             20%           Unselected AML   FC          Provided   OS         Multivariate       Age, Sex, WBC, cytogenetics, ECOG, platelets, percentage of BM and PB blasts, hemoglobin and secondary AML   2.78(2.04--3.70)
                                                                           Provided   RFS        Multivariate                                                                                                                    2.97(1.28--6.89)
  Cerny          RC             1%            Unselected AML   FC          Provided   OS         Univariate         \-                                                                                                           1.07(0.40--2.81)
  Miltiades      RC             10%           Unselected AML   FC          KM         OS         Univariate         \-                                                                                                           1.79(1.08--2.94)
                                                                           KM         RFS        Univariate                                                                                                                      1.36(1.04--1.79)
  Nakase         PC             Mean          Non-M3           FC          KM         OS         Univariate         \-                                                                                                           2.38(1.69--3.33)
  Ikegawa        RC             10%           Unselected AML   FC          Provided   OS         Multivariate       Significant factors from univariate analysis                                                                 2.69(1.14--5.12)
                                                                           Provided   DFS        Multivariate                                                                                                                    2.63(1.46--4.73)
  Bołkun         RC             Median        Non-M3           FC          Provided   OS         Multivariate       NR                                                                                                           2.72(1.31--5.62)
  Fujiwara       RC             10%           Unselected AML   FC          Provided   OS         Multivariate       Cytogenetic, Age, Disease statue, PS                                                                         1.30(0.70--2.30)
                                                                           Provided   EFS        Multivariate                                                                                                                    2.10(1.03--4.10)
  Allan          RC             10%           Non-M3           FC          Provided   OS         Univariate         \-                                                                                                           2.02(1.06--3.82)
  Du             PC             80%           Unselected AML   qPCR        Provided   OS         Multivariate       Age, Secondary AML, Cytogenetics                                                                             3.45(1.84--6.46)
                                                                           Provided   RFS        Multivariate                                                                                                                    2.17(1.28--5.35)

Abbreviations: AML, acute myeloid leukemia; RC, retrospective cohort; PC, prospective cohort; BM, bone marrow; PB, peripheral blood; FC, flow cytometry; NR, not reported; qPCR, quantitative polymerase chain reaction; WBC, white blood cells; Non-M3, patients diagnosed with acute non-promyelocytic myeloblastic leukemia; ECOG, Eastern Cooperative Oncology group; PS, performance statues; OS, overall survival; RFS, relapse-free survival; DFS, disease-free survival; EFS, event-free survival.

Association between CD25 expression and OS of AML {#sec009}
-------------------------------------------------

Among the ten studies, 7 studies provided the HR and 95% CI value with the other three articles presenting the indirect survival data in the form of Kaplan Meier curves. The summary HR for OS was 2.27 (95%CI: 1.95--2.64) ([Fig 2](#pone.0236124.g002){ref-type="fig"}), indicating that high CD25 expression was inversely correlated with OS, there was no significant heterogeneity among the studies (I^2^ = 19%), so fixed model was applied to combine the results. In addition, subgroup analyses also suggested high CD25 expression was a poor prognostic factor in all above mentioned stratified strategies with low or moderate heterogeneity. [Table 2](#pone.0236124.t002){ref-type="table"} listed the detail pooled results.

![Forest plot for overall survival (OS) outcome of CD25 expression in AML patients.](pone.0236124.g002){#pone.0236124.g002}

10.1371/journal.pone.0236124.t002

###### Results of overall and subgroup analyses in the prognostic meta-analysis.
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                     OS                                 DFS/RFS/EFS                            
  ------------------ ---- ------------------- ---- ---- ------------- ------------------- ---- ----
  Overall            10   2.27 (1.95--2.64)   19   F    6             1.77 (1.44--2.17)   46   F
  Ethnicity                                                                                    
  Caucasian          6    2.25 (1.86--2.73)   12   F    3             2.08 (1.13--3.83)   65   R
  Asian              4    2.30 (1.79--2.96)   44   F    3             2.33 (1.59--3.40)   0    F
  Uni/multivariate                                                                             
  Univariate         5    2.04 (1.65--2.51)   0    F    2             1.85 (0.88--3.91)   73   R
  Multivariate       5    2.56 (2.05--3.19)   35   F    4             2.43 (1.72--3.43)   0    F
  Detection Method                                                                             
  FC                 9    2.21 (1.89--2.59)   13   F    5             2.11 (1.43--3.12)   55   R
  Non-FC             1    3.45 (1.84--6.46)        \-   1             2.17 (1.06--4.44)   \-   \-
  Cut-off value                                                                                
  10%                4    1.90 (1.45--2.50)   0    F    3             2.53 (1.72--3.72)   0    F
  others             6    2.46 (2.05--2.96)   20   F    3             1.81 (1.13--2.92)   50   R
  Subtype                                                                                      
  AML as a whole     6    2.13 (1.53--2.97)   51   R    5             1.70 (1.37--2.10)   44   F
  AML without M3     4    2.23 (1.78--2.79)   0    F    1             2.97 (1.40--6.30)   \-   \-

Abbreviations: OS, overall survival; RFS, relapse-free survival, DFS, disease-free survival; EFS, event-free survival; FC, flow cytometry; M3, acute promyelocytic myeloblastic leukemia; OS, overall survival; RFS, relapse-free survival, DFS, disease-free survival; EFS, event-free survival; FC, flow cytometry; F fixed effects model; R random effects model; HR, hazard ratio; CI, confidence interval.

Hazard ratios (HRs) for each trial are represented by the squares, and the horizontal lines crossing the square stand for the 95% confidence intervals (CIs). The diamonds represent the estimated pooled effect of the overall outcome for OS in patients with AML. A HR higher than 1 would indicate that CD25 overexpression is associated with worse OS.

Association between CD25 expression and DFS/RFS/EFS of AML {#sec010}
----------------------------------------------------------

Six studies with 981 AML patients reported the impact of CD25 expression on DFS/RFS/EFS. The pooled HR indicated that CD25 expression was inversely correlated with DFS/RFS/EFS in all studies, the difference was statistically significant with a pooled HR of 1.77 (95%CI: 1.44--2.17) ([Fig 3](#pone.0236124.g003){ref-type="fig"}). The heterogeneity was not significant (I^2^ = 46%), so fix effect model was used. Meanwhile, subgroup analyses obtained similar results ([Table 2](#pone.0236124.t002){ref-type="table"}).

![Meta-analysis of the association between CD25 expression and DFS/RFS/EFS in patients with AML.](pone.0236124.g003){#pone.0236124.g003}

Hazard ratios (HRs) for each trial are represented by the squares, and the horizontal lines crossing the square stand for the 95% confidence intervals (CIs). The diamonds represent the estimated pooled effect of the overall outcome for combined disease-free survival (DFS), relapse free survival (RFS) and event free survival (EFS) in patients with AML. A HR higher than 1 would indicate that CD25 overexpression is associated with worse DFS/RFS/EFS.

Publication bias {#sec011}
----------------

As shown in [Fig 4](#pone.0236124.g004){ref-type="fig"}, the funnel plots were symmetrical, indicating publication bias was not detected in the overall analysis of 10 enrolled studies.

![Funnel plot of studies correlating overall survival and CD25 expression in AML patients.](pone.0236124.g004){#pone.0236124.g004}

Each included study represented by one circle. The funnel plot measures the study size standard error and precision on the vertical axis as a function of effect size on the horizontal axis.

Discussion {#sec012}
==========

Clinical outcomes in patients with of AML depend on different prognostic factors, including age, statues, and the molecular characteristics and cytogenetic of the leukemic clone. Although progresses have been made in diagnosis and treatment over the past decades, because of the poor response of adjunct therapy and high recurrence rate, the overall prognosis of AML is still unsatisfactory \[[@pone.0236124.ref022]\]. Thus, it is crucial to find effective prognostic biomarkers to help to make clinical decisions and improve outcomes for AML treatments. The prognostic value of CD biomarkers has been increasingly recognized in AML clinical research in the past few years, some of them are usually shown to offer adverse clinical outcomes. CD25 is considered to be one of the candidate markers of prognosis for a wide range of malignant tumors and has been well investigated in AML, however, no comprehensive analysis have been made based on the available data. Thus, we performed the present meta-analysis to investigate the association of CD25 expression with AML prognosis.

In the present study, the relationship between CD25 overexpression and prognosis in AML was initially investigated. The pooled results indicated that increasing CD25 expression was significantly correlated with inferior outcomes for AML, the unfavorable impact was still significant in subgroup analyses across ethnicity, age group, AML subtype, cut-off value, statistical methodologies and detection method, indicating that CD25 expression is an independent prognostic factor for patients with AML. Although the analysis were statistically significant, the mechanisms that cause the difference among AML patients remain obscure. The putative role of CD25 dependent signaling pathways in pathogenesis of AML has not yet been well-accepted. In human chronic myelogenous leukemia (CML), LSCs are consisted of composed of CD25-positive and -negative populations, while the CD25 positive cell can be stimulated and associate with IL-2 pos cells in the BM microenvironment, suggesting that targeting IL-2/CD25 axis may have a functional role in nurturing LSCs \[[@pone.0236124.ref023]\]. However, previous study also reported that CD25 serves as a growth-suppressing molecule in CML stem and progenitor cells \[[@pone.0236124.ref024]\]. In human AML, CD25 is also expressed in LSC, but the components CD132 and CD122 consist the IL-2 receptor with CD25 are lacked, which indicating the signaling signature of CD25 in maintaining and generating leukemia may be different that in CML \[[@pone.0236124.ref013]\].

This meta-analysis indicated that CD25 overexpression is an indicator of poor prognosis for patients with AML. Where the majority of research had focused on hematological malignancies \[[@pone.0236124.ref025]\], there have been studies paying attention to the prognostic value of CD25 in solid tumors \[[@pone.0236124.ref026]--[@pone.0236124.ref028]\]. Liu et al suggested that higher percent of circulating CD4+CD25+CD127 T cells can predict OS and chemotherapeutic response in patients with unresectable pancreatic cancer \[[@pone.0236124.ref027]\]. Dutsch-Wicherek et al also found that patients with serous adenocarcinomas had significantly CD25+ lymphocytes T levels compared to those patients with non-serous types \[[@pone.0236124.ref026]\]. There analyses identified CD25 may be attributable to the plasticity of T cell subsets. Furthermore, high CD 25 expression was found to be independently correlated with advanced cytogenetics and complete remission rate and plays an important role in metastasis \[[@pone.0236124.ref015], [@pone.0236124.ref020]\], possibly though activation of signal transducer and activator of transcription (STAT) pathways in response to IL-2 \[[@pone.0236124.ref029]\], and Cytotoxic T Lymphocyte-associated protein (CTLA-4) \[[@pone.0236124.ref030]\]. In summary, the pooled results of this meta-analysis supported the hypothesis that CD25 overexpression affects AML progression through direct or indirect signaling pathways, leading a poor outcome of AML.

There do exist some limitations in the present study. First, the number of the enrolled studies was relatively small, only six included studies evaluated the association of CD25 expression with DFS/RFS/EFS, and the sample size in majority of included studies were limited (\<100). Secondly, the cut-off values determining positive and negative CD25 expression varied among the studies, which may also affect the reliability of the analysis results. Third, only literatures published in English were included. Accordingly, to address these limitations, a large multicenter study with uniform evaluation methods (uniformly applying unified detecting method and suitable CD25 positive threshold) may be helpful to enhance the reliability of the results.

In conclusion, CD25 expression was a risk factor for patients with AML, the patients with higher CD25 expression had a significant adverse survival rate. This information may provide important predictive information on AML prognosis and be helpful in directing clinical therapy. Meanwhile, it may also serve as a valuable molecular to develop target drugs for improving the prognosis of AML patients.
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